ATE450265T1 - Pharmazeutische mischung zur behandlung von krebs,die dioxolan nukleosidanalogen enthält - Google Patents

Pharmazeutische mischung zur behandlung von krebs,die dioxolan nukleosidanalogen enthält

Info

Publication number
ATE450265T1
ATE450265T1 AT02713967T AT02713967T ATE450265T1 AT E450265 T1 ATE450265 T1 AT E450265T1 AT 02713967 T AT02713967 T AT 02713967T AT 02713967 T AT02713967 T AT 02713967T AT E450265 T1 ATE450265 T1 AT E450265T1
Authority
AT
Austria
Prior art keywords
treatment
nucleoside analogues
cancer containing
dioxolane nucleoside
pharmaceutical mixture
Prior art date
Application number
AT02713967T
Other languages
English (en)
Inventor
Francis J Giles
Hagop M Kantarjian
Jacques Jolivet
Original Assignee
Shire Canada Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shire Canada Inc filed Critical Shire Canada Inc
Application granted granted Critical
Publication of ATE450265T1 publication Critical patent/ATE450265T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
AT02713967T 2001-03-23 2002-03-25 Pharmazeutische mischung zur behandlung von krebs,die dioxolan nukleosidanalogen enthält ATE450265T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US27797501P 2001-03-23 2001-03-23
US33060101P 2001-10-25 2001-10-25
PCT/CA2002/000426 WO2002076472A2 (en) 2001-03-23 2002-03-25 Pharmaceutical combinations for the treatment of cancer comprising dioxolane nucleoside analogs

Publications (1)

Publication Number Publication Date
ATE450265T1 true ATE450265T1 (de) 2009-12-15

Family

ID=26958821

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02713967T ATE450265T1 (de) 2001-03-23 2002-03-25 Pharmazeutische mischung zur behandlung von krebs,die dioxolan nukleosidanalogen enthält

Country Status (13)

Country Link
US (2) US6800639B2 (de)
EP (1) EP1370270B1 (de)
JP (1) JP4391087B2 (de)
KR (1) KR20040018341A (de)
AT (1) ATE450265T1 (de)
CA (1) CA2441568A1 (de)
DE (1) DE60234577D1 (de)
HU (1) HUP0400314A3 (de)
MX (1) MXPA03008623A (de)
NO (1) NO20034204L (de)
NZ (1) NZ528394A (de)
PL (1) PL365285A1 (de)
WO (1) WO2002076472A2 (de)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2383259A1 (en) 2002-04-23 2003-10-23 Celator Technologies Inc. Synergistic compositions
US20080075762A1 (en) * 2001-10-03 2008-03-27 Paul Tardi Compositions for delivery of drug combinations
US7850990B2 (en) * 2001-10-03 2010-12-14 Celator Pharmaceuticals, Inc. Compositions for delivery of drug combinations
US8383605B2 (en) * 2002-07-30 2013-02-26 Aeterna Zentaris Gmbh Use of alkylphosphocholines in combination with antimetabolites for the treatment of benign and malignant oncoses in humans and mammals
JP2005535688A (ja) * 2002-07-30 2005-11-24 ツェンタリス ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗腫瘍医薬との組合せにおけるアルキルホスホコリンの使用
WO2004052369A1 (en) * 2002-12-06 2004-06-24 Shire Biochem Inc. Pharmaceutical combinations and methods for the treatment of leukemia
CA2527126A1 (en) * 2003-04-02 2004-10-14 Paul Tardi Nano-sized vehicles transporting a therapeutic agent and at least one drug resistance modulator for the treatment of multi drug resistance
CN104383542B (zh) 2003-04-08 2017-09-26 普罗热尼奇制药公司 包含甲基纳曲酮的药物配方
US20040248915A1 (en) * 2003-04-25 2004-12-09 Jacques Jolivet Method for administration of troxacitabine
EP2263694B1 (de) * 2003-09-25 2013-06-12 Astellas Pharma Inc. Antitumormittel, enthaltend den Histon-deacetylase-inhibitor FK228 und den Topoisomerase-II-Inhibitor Doxorubicin
US9662325B2 (en) 2005-03-07 2017-05-30 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US8518962B2 (en) 2005-03-07 2013-08-27 The University Of Chicago Use of opioid antagonists
US8524731B2 (en) 2005-03-07 2013-09-03 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
MX2007010833A (es) 2005-03-07 2009-02-17 Univ Chicago Uso de antagonistas opioides para atenuar proliferacion y migracion de células endoteliales.
AR057035A1 (es) 2005-05-25 2007-11-14 Progenics Pharm Inc SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS
AR057325A1 (es) 2005-05-25 2007-11-28 Progenics Pharm Inc Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos
AU2006291165B2 (en) 2005-09-12 2013-03-14 The Ohio State University Research Foundation Compositions and methods for the diagnosis and therapy of BCL2-associated cancers
KR20090057050A (ko) * 2006-09-01 2009-06-03 유니버시티 오브 조지아 리서치 파운데이션, 인코포레이티드 암치료를 위한 트록사시타빈 전구약물
AU2008233133B2 (en) 2007-03-29 2014-03-27 Progenics Pharmaceuticals, Inc. Crystal forms of (R) -N-methylnaltrexone bromide and uses thereof
MX2009010515A (es) 2007-03-29 2009-10-19 Wyeth Corp Antagonistas del receptor opioide periferico y usos de los mismos.
MX2009010552A (es) 2007-03-29 2009-12-14 Progenics Pharm Inc Antagonistas de receptor de opioide periferico y usos de los mismos.
WO2009023845A2 (en) * 2007-08-15 2009-02-19 The Board Of Regents Of The University Of Texas System Combination therapy with synthetic triterpenoids and gemcitabine
RS58486B1 (sr) 2008-01-11 2019-04-30 Reata Pharmaceuticals Inc Sintetički triterpenoidi i metode njihove upotrebe u tretmanu bolesti
KR101581480B1 (ko) 2008-02-06 2015-12-30 프로제닉스 파머슈티컬스, 인코포레이티드 (ｒ),(ｒ)-2,2'-비스-메틸날트렉손의 제조법 및 용도
CA2719134C (en) 2008-03-21 2015-06-30 The University Of Chicago Treatment with opioid antagonists and mtor inhibitors
US20100004193A1 (en) * 2008-07-07 2010-01-07 Fondazione Per La Ricerca Biomedica Avanzata Onlus - Istituto Veneto Di Medicina Molecolare Combination therapy
CA2676881C (en) 2008-09-30 2017-04-25 Wyeth Peripheral opioid receptor antagonists and uses thereof
WO2011123691A1 (en) 2010-03-31 2011-10-06 Keryx Biopharmaceuticals, Inc. Perifosine and capecitabine as a combined treatment for cancer
EP2558105B1 (de) * 2010-04-12 2019-11-20 Reata Pharmaceuticals, Inc. Bardoxolon-methyl zur behandlung von obesität
JP7337539B2 (ja) * 2018-06-21 2023-09-04 メディヴィル・アクチエボラーグ 白血病療法のための塩基修飾シチジンヌクレオチド

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5041449A (en) 1988-04-11 1991-08-20 Iaf Biochem International, Inc. 4-(nucleoside base)-substituted-1,3-dioxolanes useful for treatment of retroviral infections
US5270315A (en) 1988-04-11 1993-12-14 Biochem Pharma Inc. 4-(purinyl bases)-substituted-1,3-dioxlanes
US6350753B1 (en) * 1988-04-11 2002-02-26 Biochem Pharma Inc. 2-Substituted-4-substituted-1,3-dioxolanes and use thereof
US5817667A (en) 1991-04-17 1998-10-06 University Of Georgia Research Foudation Compounds and methods for the treatment of cancer
WO1992018517A1 (en) 1991-04-17 1992-10-29 Yale University Method of treating or preventing hepatitis b virus
IL115156A (en) * 1994-09-06 2000-07-16 Univ Georgia Pharmaceutical compositions for the treatment of cancer comprising 1-(2-hydroxymethyl-1,3-dioxolan-4-yl) cytosines
ES2333399T3 (es) * 1999-03-29 2010-02-22 Shire Canada Inc. Metodos para tratar una leucemia.
US20030013660A1 (en) * 2000-10-13 2003-01-16 Shire Biochem Inc. Dioxolane analogs for improved inter-cellular delivery
US20040248915A1 (en) * 2003-04-25 2004-12-09 Jacques Jolivet Method for administration of troxacitabine

Also Published As

Publication number Publication date
JP4391087B2 (ja) 2009-12-24
KR20040018341A (ko) 2004-03-03
EP1370270A2 (de) 2003-12-17
HUP0400314A2 (hu) 2004-08-30
EP1370270B1 (de) 2009-12-02
CA2441568A1 (en) 2002-10-03
NO20034204L (no) 2003-11-21
HUP0400314A3 (en) 2006-02-28
PL365285A1 (en) 2004-12-27
NZ528394A (en) 2005-06-24
WO2002076472A2 (en) 2002-10-03
WO2002076472A3 (en) 2003-04-10
US6800639B2 (en) 2004-10-05
US20050004081A1 (en) 2005-01-06
JP2004525142A (ja) 2004-08-19
NO20034204D0 (no) 2003-09-22
DE60234577D1 (de) 2010-01-14
US20030083316A1 (en) 2003-05-01
MXPA03008623A (es) 2004-05-21

Similar Documents

Publication Publication Date Title
ATE450265T1 (de) Pharmazeutische mischung zur behandlung von krebs,die dioxolan nukleosidanalogen enthält
SE0100568D0 (sv) Compounds
AU2002236765A1 (en) Pharmaceutical combination for the treatment of cancer containing a 4-quinazolineamine and another anti-neoplastic agent
DE60030741D1 (de) Chinazoline verbindungen als heilmittel
BR0212078A (pt) Método de tratar ou prevenir uma doença relacionada com amilóide em um paciente, composição farmacêutica, composto quìmico, e, uso de um composto
DE602004028841D1 (de) Purin nucleoside für die behandlung von durch flavividrae verursachten krankheiten, einschliesslich hepatitis c
DE50311898D1 (de) Fredericamycin-derivate als arzneimittel zur tumorbehandlung
AP1782A (en) Use of compounds ?-D or ?-L nucleoside for treating hepatitis C virus.
ATE365720T1 (de) Agonisten von beta-adrenorezeptoren
SE0100567D0 (sv) Compounds
BRPI0515896A (pt) composto ou um sal ou éster farmaceuticamente aceitável do mesmo, método para o tratamento ou profilaxia de um hospedeiro infectado com uma infecção por flavivìrus, pestivìrus ou hepacivìrus, e, composição farmacêutica para o tratamento de um hospedeiro infectado com uma infecção por flavivìrus, pestivìrus ou hepacivìrus
MXPA04005156A (es) Antagonistas del receptor de adenosina a2a.
IS6558A (is) Blandaðar sjúkdómsmeðferðir með æðaskaðandi virkni
GB0130677D0 (en) Medicaments and novel compounds
SE0100566D0 (sv) Compounds
ATE386523T1 (de) Synergistische pharmazeutische zusammensetzungen zur behandlung bzw. prophylaxe von diabetes
EE200200087A (et) Kompositsioon hepatotsellulaarse kartsinoomi raviks
WO2004007676A3 (en) Combination therapy for the treatment of neoplasms
HUP9801022A2 (hu) Eljárás aldóz reduktáz inhibítor alkalmazása diabetikus szívizom-betegség megelőzésére vagy megfordítására
ATE245444T1 (de) Pharmazeutische zusammensetzung, enthaltend peg- asparaginase, für die behandlung von hiv infektionen
SE0004101D0 (sv) New use
ATE447953T1 (de) Pharmazeutische zusammensetzungen zur behandlung von leishmaniasis
SE0101692D0 (sv) Compounds
ATE253938T1 (de) Pharmazeutische kombination von antiviralen wirkstoffen
AR022130A1 (es) Nuevos derivados de arilalcanoilo, los procesos para su preparacion, uso y las composiciones farmaceuticas que los contienen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties